Canada Purchases Additional 4 Million Doses of Moderna’s COVID-19 Vaccine

Rhea-AI Summary

Moderna (Nasdaq: MRNA) has announced a new order commitment from the Canadian Government for an additional 4 million doses of its COVID-19 vaccine, bringing the total to 44 million doses. This increase highlights the Canadian Government's efforts to ensure vaccine availability for its citizens. Moderna's CEO, Stephane Bancel, expressed appreciation for this collaboration and emphasized the confidence in the vaccine's efficacy. Health Canada previously authorized the vaccine for individuals aged 18 and older, demonstrating continued regulatory support for Moderna's mRNA technology.

Positive

• Canadian Government increases order of Moderna COVID-19 vaccine by 4 million doses to total 44 million
• CEO emphasizes confidence in the vaccine amid partnership with Canadian government
• Health Canada has authorized the Moderna COVID-19 vaccine for adults 18 and older

Negative

• None.

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Canadian Government has increased its confirmed order commitment by 4 million doses of the COVID-19 Vaccine Moderna bringing its confirmed order commitment to 44 million doses. This increase reflects continued efforts by the Canadian Government to secure access to safe and effective COVID-19 vaccines for Canadian citizens.

“We appreciate our collaboration with the Canadian government as we seek to defeat the pandemic with our vaccine. Today’s increased supply agreement from the Canadian government reaffirms the confidence in Moderna’s COVID-19 vaccine,” said Stephane Bancel, Chief Executive Officer of Moderna.

On December 23, Health Canada authorized the COVID-19 Vaccine Moderna for the immunization of people 18 years of age and older under an Interim Order.

Authorized Use

Moderna COVID-19 Vaccine (mRNA-1273 SARS-CoV-2 vaccine) is indicated for active immunization against coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in individuals 18 years of age and older.

About Moderna

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. The company’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing Moderna the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune and inflammatory diseases, independently and with strategic collaborators.

Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co., Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense, and BARDA. Moderna has been named a top biopharmaceutical employer by Science for the past six years. To learn more, visit www.modernatx.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the Company’s supply and distribution of the Moderna COVID-19 Vaccine to the Canadian Government. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could”, “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others: the fact that there has never been a commercial product utilizing mRNA technology approved for use; the fact that the rapid response technology in use by Moderna is still being developed and implemented; the safety, tolerability and efficacy profile of the Moderna COVID-19 Vaccine observed to date may change adversely in ongoing analyses of trial data or subsequent to commercialization; despite having ongoing interactions with the FDA or other regulatory agencies, the FDA or such other regulatory agencies may not agree with the Company’s regulatory approval strategies, components of our filings, such as clinical trial designs, conduct and methodologies, or the sufficiency of data submitted; Moderna may encounter delays in meeting manufacturing or supply timelines or disruptions in its distribution plans for the Moderna COVID-19 Vaccine; whether and when any biologics license applications and/or emergency use authorization applications may be filed and ultimately approved by regulatory authorities; potential adverse impacts due to the global COVID-19 pandemic such as delays in regulatory review, manufacturing and clinical trials, supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy; and those other risks and uncertainties described under the heading “Risk Factors” in Moderna’s most recent Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210212005486/en/

FAQ

What is the recent order commitment by the Canadian Government for Moderna (MRNA)?

The Canadian Government has increased its confirmed order commitment for Moderna's COVID-19 vaccine by 4 million doses, totaling 44 million doses.

What does the increase in vaccine doses indicate for Moderna (MRNA)?

The increase reflects the Canadian Government's ongoing efforts to secure access to effective COVID-19 vaccines for its citizens, indicating strong demand.

Has Health Canada authorized the Moderna (MRNA) vaccine?

Yes, Health Canada has authorized the Moderna COVID-19 vaccine for individuals aged 18 and older.

Who is the CEO of Moderna (MRNA) and what did he say about the vaccine order?

Stephane Bancel is the CEO of Moderna, and he expressed appreciation for the collaboration with the Canadian government and highlighted the confidence in the vaccine.